Skip to main content

Melodi Javid Whitley, MD, PhD

First Year Resident
Start Year
2018

What are your career interests?

I am interested in tumor biology & immunology and how we can harness these characteristics to develop robust tumor detection tools. I have a background in molecular imaging and I am excited to bring my training to the field of Dermatology where I hope to build a career focused on the detection and treatment of melanoma and non melanoma skin cancers.

Why did you choose Duke for residency training?

I completed my medical and graduate training as well as my intern year at Duke University.  As a large clinical and academic center we are at the cutting edge of medicine and science. Every day I have the opportunity to work with excellent clinicians and researchers but I am most impressed by their humble dedication to advancing care for patients. There is also an institution-wide culture of collaboration and collegiality that makes this just an awesome place to work.

Outside of the medical center, the Triangle area offers and excellent quality of life.   We have amazing restaurants, a growing arts scene, and endless outdoor opportunities!  

Education & Training

Undergraduate:  University of Maryland, College Park, B.S. in Biochemistry, B.A. in Spanish Language and Literature, 2007
Medical School: Duke University School of Medicine, MD, PhD in Molecular Cancer Biology, 2017
Internship: Internal Medicine, Duke University, 2017-2018

Awards & Honors

  • Robert J. Fitzgerald Scholar Award, Duke Department of Pharmacology and Cancer Biology, 2016
  • Kenan Biddle Partnership Grant: Advocates for MD-PhD Women in Science, 2015
  • Duke University Graduate School Conference Travel Award, 2014
  • Oral Presentation Award, First Annual DCI Scientific Retreat, 2013
  • Kenan Biddle Partnership Grant: Joint MD-PhD Training Initiative, 2013
  • U.S. Schweitzer Fellow, Albert Schweitzer Fellowship, 2010-2011
  • Medical Scientist Training Program Grant, National Institutes of Health, 2009-2016
  • NIH Post-Baccalaureate Intramural Research Training Award, 2007-2009
Publications & Presentations

PUBLICATIONS

 

  • Huang J, Chen M, Whitley MJ, Kuo H-C, Xu ES, Walens A, Mowery YM, Van Mater D, Eward WC, Cardona DM, Luo L, Ma Y, Lopez OM, Nelson CE, Robinson-Hamm JN, Reddy A, Dave SS, Gersbach CA, Dodd RD, and Kirsch DG. Generation and Comparison of CRISPR/Cas9 and Cre-Mediated Genetically Engineered Mouse Models of Sarcoma. Nature Communications. 2017 Jul 10; 8:15999.
  • Whitley MJ, Barrow W, Craciunescu OI, Pavlis M, and Kirsch DG.  Kaposi sarcoma in a patient with post-polio syndrome.  Cutis. In Press.
  • Chitalia R, Mueller J, Fu HL, Whitley MJ, Kirsch DG, Brown JQ, Willett R, and Ramanujam N. Algorithms for differentiating between images of heterogenous tissue across fluorescence microscopes.  Biomedical Optics Express. 2016 Sep 1; 7(9): 3412-3424.
  • Bartholf DeWitt S, Eward WC, Eward CA, Lazarides AL, Whitley MJ, Ferrer JM, Brigman BE, Kirsch DG, Berg J.  A novel imaging system distinguishes neoplastic from normal tissue during resection of soft tissue sarcomas and mast cell tumors in dogs.  Veterinary Surgery.  2016 Aug; 45(6): 715-22.
  • Whitley MJ, Cardones AR, Craciunescu O, and Kirsch DG.  Externally applied high dose rate brachytherapy for deeply invasive cutaneous squamous cell carcinoma in an elderly patient.  Practical Radiation Oncology.  2016 Jul-Aug; 6(4):e141-4.
  • Ashton JR, Hoye J, Deland K, Whitley MJ, Qi Y, Moding EJ, Kirsch DG, West J, and Badea CT.  A dual energy CT study on vascular effects of gold nanoparticles in radiation therapy.  Proc. SPIE 9788, Medical Imaging 2016: Biomedical Applications in Molecular, Structural, and Functional Imaging, 97780W (March 29, 2016).
  • Fu HL, Mueller JL, Whitley MJ, Cardona DM, Willett RM, Kirsch DG, Brown JQ, Ramanujam N.  Structured Illumination Microscopy and a Quantitative Image Analysis for the Detection of Positive Margins in a Pre-Clinical Genetically Engineered Mouse Model of Sarcoma.  PLoS One.  2016 Jan 22; 11(1):e0147006.
  • Whitley MJ, Cardona DM, Lazarides AL, Spasojevic I, Ferrer JM, Cahill J, Lee CL, Snuderl M, Blazer III DG, Hwang SE, Greenup RA, Mosca PJ, Mito JK, Cuneo KC, Larrier NA, O’Reilly EK, Riedel RF, Eward WC, Strasfeld DB, Fukumara D, Jain RK, Lee WD, Griffith LG, Bawendi MG, Kirsch DG, and Brigman BE. A Mouse-human Phase I co-clinical trial of a protease-activated fluorescent probe for imaging cancer. Science Translational Medicine.  2016 Jan 6; 8(320):320ra4. *Highlighted in JAMA (Jacob JA.  Protease-Activated Fluorescent Probe Shows Promise as a Cancer Imaging Device.  JAMA.  2016; 315(12): 12-7-1218.), CBS News, and TIME.com.
  • Lazarides AL*, Whitley MJ*, Strasfeld DB, Cardona DM, Ferrer JM, Mueller JL, Fu HL, DeWitt SB, Brigman BE, Ramanujam N, Kirsch DG, and Eward WC.  A fluorescence-guided laser ablation system for removal of residual cancer in a mouse model of soft tissue sarcoma.  Theranostics.  2016 Jan 1; 6(2): 155-66.  *Co-first authors
  • Mueller JL, Fu HL, Mito JK, Whitley MJ, Chitalia R, Erkanli A, Dodd L, Cardona DM, Geradts J, Willett RM, Kirsch DG, Ramanujam N.  A quantitative microscopic approach to predict local recurrence based on in vivo intraoperative imaging of sarcoma tumor margins.  International Journal of Cancer.  2015 Nov 15;137(1): 2403-12.
  • Whitley MJ, Weissleder R, Kirsch DG.  Tailoring Adjuvant Radiation Therapy by Intraoperative Imaging to Detect Residual Cancer.  Seminars in Radiation Oncology.  2015 Oct; 25 (4):313-21.
  • Sachdeva M, Whitley MJ, Mito JK, Ma Y, Lev DC, Cardona DM, Kirsch DG.  Micro-RNA-16 suppresses metastasis in an orthotopic, but not autochthonous, mouse model of soft tissue sarcoma.  Disease Models and Mechanisms.  2015 Sep; 8(9): 1169.
  • Liu Y, Ashton JR, Moding EJ, Yuan H, Register JK, Fales AM, Choi J, Whitley MJ, Zhao X, Qi Y, Ma Y, Vaidyanathan G, Zalutsky MR, Kirsch DG, Badea CT, Vo-Dinh T.  A plasmonic gold nanostar theranostic probe for in vivo tumor imaging and photothermal therapy.  Theranostics.  2015 May 23; 5(9): 946-60.
  • Fu HL, Mueller JL, Javid MP, Mito JK, Kirsch DG, Ramanujam N, Brown JQ.  Optimization of a widefield structured illumination microscope for non-destructive assessment and quantification of nuclear features in tumor margins of a primary mouse model of sarcoma.  PLoS One.  2013 Jul 23; 8(7):e68868.
  • Cuneo KC, Mito JK, Javid MP, Ferrer JM, Yongbaek K, Lee WD, Bawendi MG, Brigman BE, and Kirsch DG.  2013. Imaging primary mouse sarcomas after radiation therapy using cathepsin-activatable fluorescent imaging agents.  International Journal of Radiation Oncology Biology Physics, 2013 May 1; 86(1): 136-42.
  • Dussupt V, Sette P, Bello NF, Javid MP, Nagashima K, and Bouamr F.  2010.  Basic residues in the nucleocapsid domain of Gag are critical for late events of HIV-1 budding.  Journal of Virology, 85(5): 2304-15.
  • Dussupt V, Javid MP, Abou-Jaoude G, Jadwin JA, de La Cruz J, Nagashima K, and Bouamr F.  2009.  The nucleocapsid region of HIV-1 Gag cooperates with the PTAP and LYPXnL late domains to recruit the cellular machinery necessary for viral budding.  PLoS Pathogens, 5(3):e1000339.
  • Ruthel G, Demmin GL, Kallstrom G, Javid MP, Badie SS, Will AB, Nelle T, Shokman R, Nguyen TL, Carra HK, Bavari S, and Aman MJ.  2005.  Association of ebola virus matrix protein VP40 with microtubules.  Journal of Virology, 79(8):4709-19. 

 

ORAL PRESENTATIONS

 

  • Whitley MJ et al. A Phase I Clinical Trial of LUM015: A Protease-activated Fluorescent Imaging Agent to Detect Cancer during Surgery.  Duke MSTP Symposium.  Durham, North Carolina. March, 2015.
  • Whitley MJ et al. A Phase I Clinical Trial of LUM015: A Protease-activated Fluorescent Imaging Agent to Detect Cancer during Surgery.  Society for Surgical Oncology 68th Annual Cancer Symposium.  Houston, Texas. March, 2015.
  • Whitley MJ et al. Molecular Imaging of Sarcoma and Normal Tissues: A Mouse-Human Phase I Co-Clinical Trial.  Connective Tissue Oncology Society 19th Annual Meeting.  Berlin, Germany.  October, 2014.
  • Whitley MJ.  Can we illuminate the path to better cancer surgery?  Duke GradX.  Durham, North Carolina.  March, 2014.
  • Whitley MJ et al. Molecular Imaging: Bringing Technology to the Operating Room.  28th National MD/PhD Student Conference.  Keystone, Colorado.  July, 2013.
  • Whitley MJ et al. Molecular Imaging: Bringing Technology to the Operating Room.  1st Annual DCI Scientific Retreat.  Durham, North Carolina.  May, 2013.
  • Whitley MJ et al. Molecular Imaging: Bringing Technology to the Operating Room.  Duke Women in Science and
  • Engineering Symposium.  Durham, North Carolina.  December, 2012.

POSTERS

 

  • Whitley MJ et al.  Molecular Imaging of Cancer and Normal Tissues: A Mouse-Human Phase I Co-Clinical Trial. 
  • Duke Radiation Oncology Imaging Program Retreat.  Durham, North Carolina. March, 2015.
  • Whitley MJ et al.  Molecular Imaging of Cancer and Normal Tissues: A Mouse-Human Phase I Co-Clinical Trial.  Southeast Symposium for MD-PhD Women in Science.  Durham, North Carolina. May, 2014.
  • Whitley MJ et al.  A Phase I study of the safety and activation of a cathepsin-activatable fluorescent cancer-specific probe LUM015. ASCO 2014.  Chicago, Illinois.  May, 2014. J Clin Oncol 32:5S, 2014 (suppl; abstr TPS11135).
  • Whitley MJ et al.  Molecular Imaging of Cancer and Normal Tissues: A Mouse-Human Phase I Co-Clinical Trial.  Duke MSTP Symposium.  Durham, North Carolina. April, 2014.
  • Javid MP et al.  Molecular Imaging: Bringing technology to the operating room.  First Tobacco Road Medical Research Symposium.  Chapel Hill, North Carolina.  November, 2013.
  • Dibble C, Javid MP, Kan M, and Taus P.  Kenan-Biddle Partnership: Joint MD-PhD Training Initiative.  Kenan-Biddle Partnerships Showcase.  Chapel Hill, North Carolina.  October 2013.
  • Javid MP et al.  Molecular Imaging: Bringing technology to the operating room.  2012 Annual Duke Department of Pharmacology and Cancer Biology Retreat.  Wrightsville Beach, North Carolina.  September, 2012.